Index

18-fluoro-2-deoxy-glucose positron emission tomography (18 FDG PET), 119
β-cells see pancreatic islet cells
β-myosin heavy chain mutation, 98, 100, 440
β-thalassemia, 430
e-capronolactone, 263

AATB see American Association of Tissue Banks (AATB)
ABCG-2 cell surface marker, 410
ABO compatibility, 93, 126, 138, 440
Acanthamoeba, 299
access to materials cells, 17–18, 327
fair/equitable, 4, 5, 6, 7, 13
ACDF (anterior cervical discectomy and fusion), 171–2, 173, 174, 176, 177
acellular dermal grafts/matrices, 221, 264–6
ACGR (Australian Corneal Graft Registry), 50, 52
ACL (anterior cruciate ligament) repair, 156, 200
acronyms, biovigilance, 51

Actifi™ implant, 207–8
Adam’s rib (Biblical story), 153
adherence; skin grafts, 243–4
adnexal skin structures, 237, 238, 255
adrenal medulla autografts, 364
adverse events see biovigilance
Aedes albopictus, 55, 56
age, 88, 230, 306, 436
ALK (anterior lamellar keratoplasty), 282
allergic reactions see also graft rejection; graft-versus-host disease (GVHD);
immunosuppression
alloimmune diseases, 88, 99–101, 440
autoimmune diseases, 88, 313, 319, 392
biovigilance networks, 49, 65, 68
peanut allergy transmission, 94
AlloDerm®, 264–6
alloimmune diseases see also graft-versus-host disease (GVHD)
lymphocyte passenger syndrome, 91, 92
neonatal
hemolytic disease of the fetus, 440
thrombocytopenia, 99–101
transmission, 88
ALS (amyotrophic lateral sclerosis), 363, 366
altruistic donation, 10, 16, 23, 24
alveolar ridge resorption, 224, 225
Alzheimer's disease, 363, 366
American Association of Orthopedic Surgeons, 24–5, 251
American Association of Tissue Banks (AATB)
biovigilance
standards, 58–9
systems development, 63–6
bone banks, 166, 167
standards for heart valve decontamination, 140
viral safety tests, 195
amnion, 249–50, 279, 285, 286–7, 290
amputees, long bone from, 153, 154
amyotrophic lateral sclerosis (ALS), 363, 366
anatomy
skin, 237, 240
teeth, 214
anemia
Diamond–Blackfan anemia, 430
Fanconi anemia, 317, 319, 430
hemolytic GVHD, 91, 92–3
aneurysm formation, 117–21, 127, 128, 131
angina, CD34+ cells, 408
animal models
amniotic membrane ocular use, 287
neural stem cell transplantation, 360–2, 364
pancreatic islet cells, 383, 384
stem cells for cardiac repair, 411, 412, 413, 415
ankylosing spondylitis, 172
anterior cervical discectomy and fusion (ACDF), 171–2, 173, 174, 176, 177
anterior cruciate ligament (ACL) repair, 156, 200
anterior eye chamber, 359, 360
anterior lamellar keratoplasty (ALK), 280–8, 293
Anthony Nolan Registry, 314
anti-Müllerian hormone (AMH), 436
antibiotics, 139–41, 223
anticoagulants, 139–41
antigen-presenting cells (APCs), 337
aorta
aneurysms, 123–4
first repair, 117
late aneurysmal degeneration, 117–18, 127, 128, 131
post-op graft infections, 119–21
characteristics, 115
stenosis, adult bicuspid, 146
valve allograft techniques, 142–3
valve homografts, 135, 136
valve prosthesis re-replacement, 147
Apligraf® (GraftSkin), 272
ART see assisted reproduction techniques (ART)
arterial allografts
aorta, 117
failure modes, 123, 124
late aneurysmal degeneration, 117–18, 127, 128, 131
post-op graft infections, 119–21
viral transmission, 82
arterial infections, 119
arthritis, 156–7, 197, 340, 341
articular cartilage, 153, 156–7, 200, 340–1
artificial insemination, 421–2, 423, 425, 431–2
assisted reproduction techniques (ART), 421–41
case studies, 431, 434, 440
current practices, 422–40
disease transmission, 95–100
donated gametes, 433–40
history, 421–2
indications, 422–3
overview, 423
post-pregnancy follow-up, 431
atherosclerosis, 114, 115, 129
attachment studies, dental, 220
audit, clinical, 25–7
Australian Corneal Graft Registry (ACGR), 50, 52
autografts
- adrenal medulla for Parkinson’s disease, 364
- bone, neurosurgery, 171, 173–5
- conjunctival limbal autografts, 279, 280, 285
- cultured epithelial, 250–1
dentistry
- history, 218
- stem cells, 229
- tooth transplantation, 230
dura mater substitutes, 184
- harvesting problems, 230, 289
- limbal stem cell source, 294
- osteochondral for small defects, 198
- serum eye-drops, 288–9, 298
- skin, 240–2, 245, 246, 254–5, 268–9

autoimmune diseases
- amyotrophic lateral sclerosis, 363, 366
- hematopoietic stem cells, 313, 319
- multiple autoimmune disease, 392
- transmission, 88
- autologous peripheral blood stem cells, 322, 323, 329–30
- autonomy of donor, 4–5, 6, 7

B cells, 336–7
bacterial infections, 75–81
- biovigilance networks, 33, 64
  - Chlamydia spp., 86, 436
  - clostridial, 25, 78, 195
  - Comomonas acidovorans, 80
  - Elizabethkingia meningoseptica, 44
  - Enterococcus faecalis, 98
  - Escherichia coli, 98, 120
- Group A streptococci, 79
- methicillin-resistant Staphylococcus aureus, 118, 120
- musculoskeletal allografts, 195–6
- Mycobacterium, 77, 85
- Mycoplasma hominis, 85, 97
- Neisseria gonorrhoeae, 436
- organ allografts, 86
- Pseudomonas aeruginosa, 81
- staphylococcal, 81, 118, 120, 246, 247
- toxin-mediated desquamation, 246
- Bagby cage, 179
- basic fibroblast growth factor 2 (FGF-2), 334
- BASK (British Association for Surgery of the Knee), 26
- BCR–ABL fusion gene, 328
- beta cells see pancreatic islet cells
- biaxial heart valve loading, 139
- bicuspid aortic stenosis, 146
- Biobrane®, 261–2
- biomechanics, 139, 173
- BioSeed-STM, 270
- biosynthetic wound dressings, 261–3
- biovigilance
  - see also disease transmission
- assisted reproduction, 432–3, 438–9
- clinical governance, 28–35
- gamete donors, 97, 435–6, 438–9, 440
- need for, 30, 52–3
- network benefits, 30
- pancreatic islet cells, 390, 391
- program/project acronyms, 51
- recognising adverse outcomes, 32–5
- surgeon’s role, 30, 32, 79
- systems development, 48–69
- AATB’s role, 63–6
- Bologna Initiative, 66
- case studies, 54, 57, 58
- current systems, 61–3
- history, 49–52
- need for, 52–3
- Project Notify, 66
- reporting requirements of authorities, 59–61
- risk management, 53–5
- standards/policies, 56–9
- universal coding, 66–7
- blastocyst culture, 426
- blood
  - see also bone marrow; hematopoietic stem cell transplantation
  - (HSCT)
- anticoagulants, 139–41
- autologous peripheral blood stem cells, 322, 323, 329–30
- cord blood, 18, 317–18, 327, 369–70
- hemolytic diseases, 91, 92–3, 439, 440
- transfusion services, 38–9
UK services, 26
US error reporting, 55
blood-mediated inflammatory reaction (BMIR), 389
BMMNCs (bone marrow mononuclear cells), 404–10
BMPs see bone morphogenetic proteins (BMPs)
body-powered prostheses, 304
Bologna Initiative, 66
bone see also bone marrow
advantages as allograft, 152
cancellous, 176
dentistry, 218, 219, 220, 222–31
bone loss, 214, 215, 216, 223
fusion
gene therapy, 182
metabolism, 172
neurosurgery, 170–88
posterior–lateral lumbar fusion, 176
preservation method vs. immune response, 175–6
principles, 172
substitutes, 165–6, 178–9, 181
tissue banks organization, 166
history of use, xiv–xv
loss, 214, 215, 216, 223, 340, 341
numbers of allografts, 73
smoking effects, 172, 177, 179
spinal, 170–2, 173, 174, 176, 177
sterilization, 73
structural allografts, 157–63
substitutes, 165–6, 178–9, 181
bone marrow
failure syndrome, 325
hematopoietic stem cell transplantation, 312–30
international regulation, 18
Klinefelter's syndrome, 19–20
mesenchymal stem cells for cardiac repair, 409–10
multipotent adult progenitor cells for cardiac repair, 409–10
passenger lymphocyte syndrome, 92
transplant ethics case study, 15–16
World Marrow Donor Association, 51
bone marrow mononuclear cells (BMMNCs), 404–10
bone morphogenetic proteins (BMPs)
dentistry, 220
INFUSE® rhBMP product, 229
neurosurgery, 179–82
orthopedics, 164–5
recombinant, 180–1, 182, 227, 229
bone-marrow-derived mesenchymal stem cells, 332–48
clinical experience, 342–4
definition/isolation/characterization, 333–4
functions, 340–1
future aspects, 344–5
immunoregulation, 339
immunosuppression by, 336–9
in vitro growth, 334–5
licensing step, 338–9
molecular mechanisms, 335
off-the-shelf use, 345, 346
tissue engineering, 346
BOOST-2 clinical trial, 406
brain see neural stem cell transplantation
British Association for Surgery of the Knee (BASK), 26
buccal mucosa, 273, 274, 294
burns surgery, 236–56
cost constraints, 254, 255
disaster planning, 252–3
future issues, 251–6
major/minor burns definitions, 237–8
present practice, 237–51
sandwich autograft/allograft skin grafting, 245, 246, 254–5
skin substitutes, 258–72, 275–6
dermal substitutes, 260–1, 263–9
epidermal substitutes, 260–3
temporary dressings, 259–60
wound healing, 237–8
Busin guide, 283
busulfan, 321–2
C-Cure clinical trial, 407
CADUCEUS clinical trial, 410
cages, neurosurgical, 178, 179, 182
calcification, vascular, 127, 128, 137, 138, 144
Canada, 59, 60, 62
cancellous bone, 176
cancer
  allograft transmission, 84
  biovigilance networks, 65
  chemotherapy, 312, 313, 434
  conditioning treatments, 16, 318–320, 324, 327
  chondrosarcoma case study, 159–60
direct transfer to surgeon, 87
  hematopoietic stem cells, 312–15, 319, 324, 325, 328–30
  hepatocellular carcinoma, 185–7
  leukemia, 15–16, 313, 329–30
  mesenchymal stem cells, 343, 344, 348
  neural stem cell proliferation control, 371–2
  organ/tissue/cells transmission risk, 84, 87–90
  osteosarcoma, 160–3
  structural bone allografts, 157–63
  tumor resection/reconstruction, 121
  vascular grafts, 121
*Candida* infections, 85
CAP (College of American Pathologies), 56–7
ε-capronolactone, 263
  cardiac magnetic resonance imaging (CMR), 412, 413, 416
  Cardio133 clinical trial, 407
cardiovascular disease
  see also aorta
cardiac repair
  stem cells, 403–17
    bone marrow mononuclear cells, 404–10
    clinical issues, 412–16
    future preparations, 410–11
    mesenchymal, 409–10
    mobilization, 411–12
    skeletal myoblasts, 404
  cardiac valves/conduits, 135–48
    alternatives to allografts, 137–8
    antibiotics/anticoagulants/
      immunomodulation, 139–41
    biomechanics, 139
  case studies, 145–8
future, 144–5
  history, 135–8
  indications for use, 141–2
  limitations of use, 137
  present, 138–43
  tissue matching requirement, 138–9
  children, 122, 141, 145–6
  gene mutation transmission by sperm
    donation, 98, 100, 440
  hypertrophic cardiomyopathy, 98, 100, 440
tuberculosis transmission, 85
Carrel, Alexis, 114, 116, 153
cartilage, 153, 156–7, 340–1
  viable chondrocytes, 194, 198–9, 200
  case studies
    allograft heart valves, 145–8
    ART disease transmission, 78, 79, 100
    assisted reproduction, 431, 434, 440
    biovigilance systems, 54, 57, 58
    burns, skin grafts, 246, 247
    clinical governance, 26, 31, 34–5, 40, 41, 44
dentistry, 231–2
  ethics, 12, 14, 15–16, 19–20
  hematopoietic stem cells, 329–30
  neurosurgical bone allografts, 185–7
  ophthalmics, 297–9
  pancreatic islet cells, 385–6, 392, 393
  structural bone allografts, 158–63
  CD cell surface markers, 333–4
  CD34+ cells, 408, 409
  CD133+ cells, 408, 409, 413, 415
  CD146 (MCAM), 334
CDC (Centers for Disease Control and Prevention, US), 55, 195, 196
CEAs (cultured epithelial autografts), 250–1
  cell surface markers, 333–4, 408, 409, 410, 413, 415
  cell-mediated immunity, 126, 127
cells, human (HC)
  cardiac repair, 403–17
  clinical governance, 23–45
dental therapy, 229
disease transmission risk, 72–101
ethical issues, 14–15, 16–19
hematopoietic stem cells, 312–30
mesenchymal stem cells, 332–48
nervous stem cells, 358–74
ophthalmic surgery, 279, 280, 285, 289–93, 294–5, 300
pancreatic islet cells, 383–400
viability
allograft heart valves, 144
chondrocytes, 194, 198–9, 200
skin, 243
Cellwave clinical trial, 407
Centers for Disease Control and Prevention (CDC), 55, 195, 196
ceramic bone substitutes, 179
certification of tissue suppliers, 39
cervical discectomy and fusion, 171–2, 173, 174, 176, 177
chemical injury, optical, 297
chemotherapy, 312, 313, 434
conditioning regimens, 320, 324, 327
reduced intensity, 318–19, 324
children
ART post-pregnancy follow-up, 431
congenital cardiac disease, 122, 141, 145–6
tetralogy of Fallot, 141, 145–6
tracheal reconstruction, 122
Chlamydia spp.
C. pneumoniae, 86
C. trachomatis, 436
cholinergic deficiency, 361–2
chondrocytes, viable, 194, 198–9, 200
chondrosarcoma case study, 159–60
chromosomal instability, 371
Chryseobacterium meningosepticum (now Elizabethkingia meningoseptica), 44
CITR (Collaborative Islet Transplant Registry), 387, 388
CJD see Creutzfeld–Jakob disease (CJD) classification
burns, 237–8
human tissues, 7–8, 305–6, 307
CLAU (conjunctival limbal autografts), 279, 280, 285
clinical audit, 25–7
clinical effectiveness, 23–45, 181, 207–8, 323–4
clinical governance
biovigilance networks, 28–35
clinical audit, 25–7
clinical effectiveness, 25–7
interdisciplinary oversight, 24, 28
case studies, 26, 31, 34–5, 40, 41, 44
disease transmission risk, 23, 24, 25, 30
hospital tissue services’ role, 35–42
physician’s role, 23–45
tissue allograft recalls, 43
clinical outcomes
composite grafts, 308–9
dead donor skin grafts, 249
hematopoietic stem cells, 315
haploidentical family member, 317
ligament grafts, 204–5
meniscus surgery, 203–4
ocular surface transplantation, 286, 287
osteochondral allografts, 204
penetrating keratoplasty, 278–9, 283
recognition of adverse, 32–5, 83–5, 86
sports medicine allografts, 203–5
three types of adverse, 49, 68
umbilical-cord blood transplantation, 318
clinical trials
conical epithelium reconstruction, 291–2
MAGIC clinical trial, 404, 406
neural stem cell transplantation, 362–6
pancreatic islet cells, 383–4, 387–90, 398–9
stem cells for cardiac repair, 405–8, 409, 410, 412–16
vascular allografts, 123
clinically-unproven tissue allografts, 40
clinicians see physicians/surgeons
clostridial infections, 25, 78, 195
CMI (collagen meniscus implant), 206–7
CMR (cardiac magnetic resonance imaging), 412, 413, 416
coding, universal, 66–7
cold ischemia time, 391
Collaborative Islet Transplant Registry (CITR), 387, 388
collagen, 206–7, 261–2, 267–9
collagen meniscus implant (CMI, Menaflex™), 206–7
College of American Pathologists (CAP), 56–7
commercialization
commercially-available BMPs, 165
ethical issues, 9–11, 16–17
family wishes case study, 12
sibling donor withdrawal case study, 15–16
WHO Guiding Principles, 10, 11
neural stem cell transplantation, 373
payment for donation, 5, 6, 15–16
unqualified suppliers, 40
communication gaps
ART-transmitted STDs, 97
biovigilance systems development case study, 57, 58
CJD/Lyodura® dura mater grafts, 82
disease transmission case study, 78, 79
Comomonas acidovorans, 80
complications
see also biovigilance; disease transmission; infection, post-op assisted reproduction, 95–100
composite grafts, 307
endothelial keratoplasty, 283
hematopoietic stem cell transplantation, 320–2
types, xv
composite grafts see vascularized composite allotransplantation (VCA)
computed tomography (CT), 119
computerized femoral ring cutting, 155
conditioning regimens, 320, 324, 327
reduced intensity, 318–19, 324
conduits see cardiovascular disease, cardiac valves/conduits
confidentiality, 6
congenital cardiac disease, 122, 141, 145–6
conjunctival defects see ocular surface diseases
conjunctival epithelial cells, 294
conjunctival limbal autografts (CLAU), 279, 280, 285
connective tissue
see also sports medicine cartilage, 153, 156–7, 200, 340–1
ligaments, 200–1, 203, 204–5
consent, legal, 6, 18–19
contractile function, cardiac, 403, 404, 406, 407, 408, 413
contracture, skin wounds, 264
contrast-enhanced computed tomography, 119
creeping substitution, 193, 245
Creutzfeldt-Jakob Disease (CJD) allograft types, 77
biovigilance networks, 65
characteristics, 73
clinical governance, 42
corneal allografts, 18, 317–18, 327, 369–70
Cornea Donor Study Investigator Group, US, 278–9
corneal epithelium reconstruction, 291–2
Cosmas, Saint, 14, 153, 302
cosmetic use, 11, 12
costs
allograft heart valves, 145
bone allografts, 167
burns surgery, 254, 255
commercially-available BMPs, 165
hematopoietic stem cells, 329
vascular allografts, 129–30
Council of Europe, 59
craters, interdental, 216, 217
creeping substitution, 193, 245
Creutzfeldt-Jakob Disease (CJD) allograft types, 77
biovigilance networks, 65
characteristics, 73
clinical governance, 42
corneal allografts, 42, 82
disease transmission, 72–101
see also bacterial infections;
Creutzfeld–Jakob Disease (CJD); genetic diseases; viral infections
allograft viability vs safety, 73–5
aortic grafts, 119–21
ART complications, 95–100, 435–6, 438–9, 440
biovigilance development, 49, 50, 68
bone allografts, 172
bone substitutes, 165–6, 181
cancer, 84, 87–90
case studies, 19–20, 78, 79, 100
clinical governance aspects, 23, 24, 25, 30
cultured skin substitutes, 269
immunologic diseases, 90–4
incidence, 74
metabolic diseases, 88, 94–5, 96
risk, 75–87
skin grafts, 247–8
sperm/ova donation, 435–6, 439, 440
DMSO (dimethylsulfoxide), 117, 131
DNA polymerase chain reaction, 429
dog model, 135
donor site morbidity
bone autografts, 171, 174, 230
skin autografts, 259
skin grafts, 241, 248
donors
donor factors, pancreatic islet cells, 390–1
donor pool insufficiency, 129, 137
donor-related disease transmission see disease transmission
hematopoietic stem cells, 325, 326
algorithms, 325, 326
selection
cancer transmission, 89
composite grafts, 306
criteria fairness, 6
sperm/ova donation, 433–40
dopaminergic innervation, 360, 361
dry eye, 288, 298
DSEAKeK (Descemet Stripping Automated Endothelial Keratoplasty), 281, 282–3, 293
Dubost, Charles, 117
dura mater allografts, 73, 80, 82, 83, 170, 183–5
durability of heart valves, 137, 142
dyskinetic movements, 365
EATB (European Association of Tissue Banks), 166
EBV (Epstein–Barr virus), 77, 90
Edmonton protocol, 386–7, 388, 398
education of surgeons/physicians, 27
effectiveness, clinical, 25–7
efficacy
ActifitTM implant, 207–8
bone substitutes, 181
clinical governance aspects, 23–45
mesenchymal stem cells, 323–4
Ehlers Danlos syndrome, 201
EK (endothelial keratoplasty), 281, 282–3, 293
Elizabethkingia meningoseptica, 44
embryo freezing, 428
embryo transfer, 426, 437
embryonic stem cells (ES)
cardiac repair, 411
neural, 358–74
CNS degenerative disorders, 358–74
pancreatic islet cells, 397
principles of primary fetal cell transplantation, 359–60
EMD (enamel matrix derivative), 227, 228
emotions, complex grafts, 307–8
enamel matrix derivative (EMD), 227, 228
endocarditis, 146
endometrial preparation, 438
endometriosis, 422
endothelial keratoplasty (EK), 281, 282–3, 293
endothelium
allograft heart valves, 140
corneal, 281, 282, 283, 284
endovascular therapies, 130, 131
endpoints, 412, 413, 415, 416
Enterococcus faecalis, 98
epidermal substitutes, 260–3
Epstein–Barr virus (EBV), 77, 90
EQSTB (European Quality Systems in Tissue Banking), 59
ES see embryonic stem cells (ES)
*Escherichia coli*, 98, 120
etanercept, 392
ethical issues, 1–21
embryonic neural stem cells, 368
human cells transplantation, 14–15, 16–19
human tissue transplantation, 5–13
fetal, 18, 364–5
normative framework, 4–5
private cord blood banking, 18
ethnicity, 17, 316
EUROCET (European Registry for Organs, Cells and Tissues), 20
Europe
biovigilance standards, 59
Directives
2004/23/EC, 60
2006/86/EC, 61
2010/53/EU, 61
biovigilance systems, 52, 60
European Association of Tissue Banks, 166
European Quality Systems in Tissue Banking, 59
European Registry for Organs, Cells and Tissues, 20
European Society of Human Reproduction and Embryology PGD Consortium, 430
European Union Standards and Training in the Inspection of Tissue Establishments project, 53–4, 61–2, 65
Guide to Safety and Quality of Organs, Tissues and Cells, 59
risk management, 55
serious adverse event reporting criteria, 55
EUSTITE (European Union Standards and Training in the Inspection of Tissue Establishments) project, 53–4, 61–2, 65
evidence-based practice, 27–8
*ex vivo* cultured limbal stem cells, 289–93
exendin-4, 397
exploitation, negative effects, 10
exports/imports, ethical aspects, 9
eye
see also ocular surface diseases; ophthalmic surgery
anterior chamber culture, 359, 360
drops, 288–9, 300
new sources, 297
serum eye drops, 288–9, 298, 300
face transplants, 303, 305, 306, 307–9
FACT/JACIE standards, 59
failure of grafts see graft failure
Fallopian tube damage, 422
Fallot’s tetralogy, 141, 145–6
false-positive bacterial contamination tests, 80
falsified documents, 54
family wishes, case study, 12
Fanconi anemia, 317, 319, 430
fascia lata, 184
FDBA (freeze-dried bone allograft), 220, 231, 232
fees, WHO Guiding Principles, 10, 11
femtosecond laser-assisted ALK, 282
femur
chondrosarcoma case study, 159–60
femoral neck fibrous dysplasia case study, 158–9
femoral ring computerized cutting, 155
frozen femoral heads, 89
osteosarcoma, 162–3
fenestrations, dental, 215, 216
fetus
see also embryonic stem cells (ES)
alloimmune thrombocytopenia, 99–101
embryonic neural stem cells, 359–60, 364–5, 367–8
ethical issues, 364–5
hemolytic disease of the newborn, 99
infection from mother/surrogate mother, 96, 99, 101
intellectual property rights, 373
stem cells, 359–60, 367–8
FGF-2 (basic fibroblast growth factor 2), 334
fibrin, 270–1, 287, 290
fibroblasts, 263, 264
fibrous dysplasia, 158–9
fibula, middle third of, 171, 173
FISH (fluorescence in situ hybridization), 429, 430
fixation, neurosurgical, 176, 177, 179
Flex HD™, 265
fluorescence in situ hybridization (FISH), 429, 430
18-fluoro-2-deoxy-glucose positron emission tomography (18 FDG PET), 119
focal demyelination, 363, 366
FOCUS clinical trial, 407
follicle-stimulating hormone (FSH), 436
Food & Drug Administration (FDA), 370
fragile X syndrome transmission, 98
freeze-dried bone allograft (FDBA), 154, 175–6, 220, 231, 232
fresh allografts, skin, 243
fresh-frozen bone allografts, 176
Friedenstein, A. J., 332
frozen allografts see cryopreservation
full thickness burns
acellular dermal matrices, 264–6
dermal substitutes, 263–9, 271–4
healing, 237, 238
skin grafting, 245, 246
temporary wound dressings, 261–3
treatment, 238–56, 259
functional cell transplants, 360–2
fungal infections
biovigilance networks, 64
Candida, 85
HCTT transmission, 75–81
organ allografts, 86
safety risk, allograft types, 77
fusion see bone, fusion
G-CSF (granulocyte colony-stimulating factor), 411
gametes see assisted reproduction techniques (ART)
gamma radiation, 197
GBR (guided bone regeneration), 220, 225, 226
gender selection, ART-related, 430
gene therapy, 182, 229, 296
generalized aggressive periodontitis, 215
genetic diseases
GnRH-deficient mouse, 361
Klinefelter's syndrome, 19–20
mutation transmission, 98, 100, 440
ocular surface disorders, 296
pre-implantation genetic diagnosis, 428–31, 432–3
sperm/ova donation, 435, 439, 440
transmission, 88, 94–5, 96, 98–9
X-linked recessive, 430
genetic stability, 371
genotyping studies, 293
gingival recession, 221, 222
global movement of tissues/cells, 28–9, 128
gonadotrophin releasing hormone (GnRH), 361, 424
gonorrhreal infection, ART-related, 97–8
good clinical governance, 23–45
graft failure, 123, 124, 142, 321
rejection
biovigilance systems, 49, 68
composite grafts, 307
corneal endothelium, 282, 286
dentistry, 218–19
skin, 248
tooth transplants, 231
unrelated donor hematopoietic stem cells, 315–16, 321
subsidence, bone allografts, 173, 177
graft-versus-host disease (GVHD), 90–4
hematopoietic stem cells, 313, 322
haploidentical family member, 316, 317
unrelated donor, 315–16, 321
mesenchymal stem cells, 342, 343, 347
granulocyte colony-stimulating factor (G-CSF), 411
Group A streptococci, 79
growth factors, 227–9, 255
see also bone morphogenetic proteins (BMPs); cytokines
GTR (guided tissue regeneration), 220, 221, 223, 224, 231, 232
Guide to Safety and Quality of Organs, Tissues and Cells (Council of Europe), 59

guided bone regeneration (GBR), 220, 225, 226

guided tissue regeneration (GTR), 220, 221, 223, 224, 231, 232

Guthrie, Claude, 114, 116

GVHD see graft-versus-host disease (GVHD)

hand transplants, 303, 304–5, 307–8, 309

haploidentical family donors, 316–17, 322, 323

haplotyping, pre-implantation, 430

HBV (hepatitis B virus), 75, 76, 77, 81, 97

HC see cells, human (HC)

HCEC (human corneal endothelial cells), 281, 282, 283, 284

hCG (human chorionic gonadotrophin), 427

HCM (hypertrophic cardiomyopathy), 98, 100, 440

HCV see hepatitis C virus (HCV)

heart see cardiovascular disease

hematopoietic stem cell transplantation (HSCT), 312–30

access/acquisition, 327

alloimmune, 314

alternatives, 328

cancer transmission, 84, 90

case studies, 329–30

choice of approach, 324, 327

complications, 320–2

different sources, 322–4

disease transmission, 88

donor selection algorithms, 325, 326

funding, 329

future aspects, 324–9

graft-versus-host disease, 90–4

haploidentical family member, 316–17, 322, 323

history, 313–19

indications, 319–20

new, 328–9

infectious disease transmission, 75–87

metabolic/genetic disease transmission, 94–5

present situation, 319–4

procedural improvements, 328

reduced-intensity transplants, 318–19

selected cell preparations for cardiac repair, 408–10

sibling, 314–15

unrelated donor, 315–16

unrelated umbilical-cord blood transplantation, 317–18, 327

heme-oxygenase-1 (HO-1), 338

hemicortical intercalary allograft, 162–3

hemolytic anemia, 91, 92–3

hemolytic disease of the fetus, 439, 440

hemophilia, 430

hepatitis B virus (HBV), 75, 76, 77, 81, 97

hepatitis C virus (HCV)

allograft recall case study, 41

biovigilance, case studies, 31, 58

sports medicine, 195

transmission by allografts, 81, 82

hepatocellular carcinoma, 185–7

hereditary disorders see genetic diseases

herpes simplex, 81

history, xiv–xv

assisted reproduction techniques, 421–2

biovigilance systems, 49–52

bone banks, 166

composite grafts, 302–3

dentistry, 218–22

heart valves/conduits, 135–8

hematopoietic stem cells, 313–19

neural stem cells, 358–67

neurosurgery

bone allografts, 170–3

bone morphogenetic proteins, 179–80

dural grafts, 183–4

fetal neural cells, 359–60

orthopedic allografts, 153–4

outcome reporting, 56–7

pancreatic islet cells, 383–7

skin grafting, 237

sports medicine, 193–4

vascular allografts, 114, 115, 116–18
HIV/AIDS transmission
assisted reproduction, 96–7, 435
muskuloskeletal allografts, 194–5
organ/tissue/HCTs, 75, 76, 77
skin grafts, 247–8
tracking failures, 57, 58
HLA see human leukocyte antigen (HLA) compatibility
HO-1 (heme-oxygenase-1), 338
hospital tissue services, 35–42
HS (hypothermic storage), 285
HSCT see hematopoietic stem cell transplantation (HSCT)
hTERt (human telomerase reverse transcriptase gene), 334–5
HTLV (human T-cell lymphotropic virus), 75, 76, 77, 81
human chorionic gonadotrophin (hCG), 427
human corneal endothelial cells (HCEC), 281, 282, 283, 284
Human Fertilisation and Embryology Authority, UK, 432, 433
human fetus see fetus
human leukocyte antigen (HLA) compatibility
composite grafts, 306
connective tissue allografts, 196
dentistry, 218
heart valves/conduits, 138
hematopoietic stem cells, 313, 314, 325
donor selection, 326
unrelated donor, 316
HLA-G, 337
HLA-identical siblings, 322, 323, 430–1
neural stem cells, 372
ocular tissues, 286, 289
skin, 248
human neonatal fibroblasts, 263, 264
human T-cell lymphotropic virus (HTLV), 75, 76, 77, 81
human telomerase reverse transcriptase gene (hTERT), 334–5
Huntington’s disease, 363, 365–6, 367
Hydroderm®, 270
hydroxyapatite, 179
6-hydroxydopamine (6-OHDA), 360, 364
hypertrophic cardiomyopathy (HCM), 98, 100, 440
hypothermic storage (HS), 285
ICSI (intracytoplasmic sperm injection), 425, 431–2
ideal systems
biovigilance, 49
skin replacement, 240, 241
small-caliber arterial grafts, 128–9
vascular grafts, 116
idiopathic (autoimmune)
thrombocytopenia purpura (ITP), 94
IDO (2,3-dioxygenase), 337, 338
IFN-γ (interferon-γ), 338, 339
iliac crest bone, 171, 173, 174, 175, 218
imaging studies, 119, 372, 412
Immune Tolerance Network (ITN) Clinical Islet Transplant Trial, 387
immune-mediated diseases
see also graft-versus-host disease (GVHD); HIV/AIDS transmission
autoimmune thrombocytopenia, 94, 99–101
HSC donor selection, 325
mesenchymal stem cells, 343
passenger lymphocyte syndrome, 91, 92
transmission risk, 90–4
immunogenicity, 126–7, 140, 143, 196
immunoglobulin (Ig)-deficiency, 95
immunoregulation, 139–41, 339, 342–4
immunosuppression
composite grafts, 307
MSC-mediated, 335–9
neural stem cell transplantation, 372
ocular surface transplantation, 286, 297
pancreatic islet cells, 384, 385, 394, 393–5
skin graft survival, 248
in oculo transplantation, 359, 360
in vitro fertilization (IVF), 421–41
blastocyst culture/transfer, 426
disease transmission, 95–100
embryo transfer, 426
gamete preservation, 427–8
gender selection, 430
indications, 422–3
insemination technique, 423–4
insemination/ICSI, 425, 431–2
luteal support, 426–7
ovocyte retrieval, 425
ovarian stimulation, 424–5, 427
pre-implantation genetic diagnosis, 428–30, 431
in vitro MSCs growth, 334–5
in vivo neural stem cell stability, 371, 372
incoming allograft inspection/acceptance, 38
indium-111-labeled leukocyte imaging, 119
induced pluripotent cells (iPS), 411
infections, post-op
see also bacterial infections; disease transmission; fungal infections; viral infections
arterial, 119
endocarditis, 146
HCV case study, 31
HSCT-related, 320
knee surgery, 31, 34–5, 196
peripheral vascular grafts, 124–5
pre-implantation testing, 80–1
serum-based eye drops, 289
skin substitute problems, 269
sources, case studies, 34–5, 44
vascular, 119
infertility
GnRH-deficiency, 361
treatments see assisted reproduction techniques (ART)
INFUSE® rhBMP product, 229
inherited diseases see genetic diseases
insemination, artificial, 421–2, 423, 425, 431–2
inspection of allografts, 38, 53–4, 61–2, 65
insulin independence, 383–400
Integra®, 254–5, 267–9
intellectual property rights, 373
intercalary allograft reconstruction, 159–60
interdental craters, 216, 217
interdisciplinary oversight, 24, 28
interferon-γ (IFN-γ), 338, 339
interleukin-1β (IL-1β), 338
internal fixation, 176, 177, 179
international aspects, 5, 18, 54
International Registry on Hand and Composite Tissue Transplantation, 308
International Ross Registry, 50
International Society for Cytotherapy, 332
International Xenotransplantation Association, 395
interposition vascular conduits, 121, 122
intrabony dental defects, 216
intracytoplasmic sperm injection (ICSI), 425, 431–2
investigations
clinical governance, 41, 42–3
disease transmission, 78, 79
infection sources, 34–5, 41
iPS (induced pluripotent cells), 411
ISL-1 cell surface marker, 410
islet cells see pancreatic islet cells
ITN (Immune Tolerance Network) Clinical Islet Transplant Trial, 387
ITP (idiopathic (autoimmune) thrombocytopenia purpura), 94
IVF see in vitro fertilization (IVF)
Japan, CJD/dura mater allografts, 183–4
joint diseases, 156–7, 197, 340, 341
joint replacement/reconstruction see orthopedics
joint stability, knee surgery, 197–8
keratinocyte growth factor (KGF), 263, 264
keratinocytes, 265, 269–71
keratolimbal allograft transplantation (KLAL), 279, 289, 297
keratoplasty, 278–86, 293, 300
Kit cell surface marker, 410
Klinefelter’s syndrome, 19–20
knee surgery
   anterior cruciate ligament, 156, 200
biovigilance case study, 31
clinical governance, 26, 34–5, 44
infection case studies, 78, 79
osteosarcoma, 162–3
sports medicine, 193, 194, 196, 197–201

labeling, biovigilance, 29
D,L-lactic trimethylene carbonate, 263
lamellar keratoplasty (LK), 280–8, 293
large vessels, vascular surgery, 114–31
late aneurysmal degeneration, 117–18, 127, 128, 131
Late TIME clinical trial, 406
LCMV (lymphocytic choriomeningitis virus), 86
left ventricular ejection fraction (LVEF), 404, 405, 406, 407, 408, 413
left ventricular end diastolic volume (LVEDV), 413
left ventricular outflow tract (LVOT) repair, 137–8
leukemia, 15–16, 313, 329–30
Lexer, E., 153, 154
life-saving surgery, 75
ligament grafts, 200–1, 203, 204–5
limbal stem cells, 279, 280, 285
deficiency (LSCD), 279, 289, 290, 294–5
ex vivo culture, 289–93
Lin28 transcription factor, 411
lineage-restricted progenitor cells, 404
living donation
   ethical issues, 9
   interposition vascular conduits, 121
LR-CLAL, 279, 285, 286, 289
skin, 248
living-related conjunctival limbal allograft (LR-CLAL), 279, 285, 286, 289
immunosuppression, 286
LK (lamellar keratoplasty), 280–8, 293
localized aggressive periodontis, 215
long bone from amputees, 153, 154
look-back investigations, 41, 43
LR-CLAL (living-related conjunctival limbal allograft), 279, 285, 286, 289
LSCD (limbal stem cell deficiency), 279, 289, 290, 294–5
luteal support for ART, 426–7
LVEDV (left ventricular end diastolic volume), 413
LVEF (left ventricular ejection fraction), 404, 405, 406, 407, 408, 413
LVOT (left ventricular outflow tract) repair, 137–8
lymphoblastic leukemia, 313, 329–30
lymphocytes, passenger syndrome, 91, 92
lymphocytic choriomeningitis virus (LCMV), 86
Lyodura® dura mater allografts, 82, 183
lyophilized allografts see freeze-dried allografts
Macewen, Sir William, 153, 193
MAGIC clinical trial, 404, 406
magnetic resonance imaging (MRI), 372, 412, 413, 416
major accidents, 252–3
major burns, 238–56
male factor infertility, 423, 431–2
malignant transformation see also cancer
   mesenchymal stem cells, 344, 348
Mankin, Dr Henry, xviii
manufacturing, islet cells, 391
MAPCs (multipotent adult progenitor cells), 334, 409–10
MARVEL clinical trial, 406
mass casualty incidents, 252–3
Matriderm®, 267, 268
MDR-1 cell surface marker, 410
mechanical heart valves, 147–8
mechanical stress see biomechanics
media attention, complex grafts, 14
Medical Director role, 35, 36, 43
medical error, 33, 53–5
MedWatch Program, 60
Menaflex™ collagen meniscus implant, 206–7
meniscus

sports medicine, 193, 199
allografts, 194, 197–8
irreparable tears, 205–8
partial replacement, 205–8
sizing, 202–3
mentally-unstable recipients, 14
mesenchymal stem cells (MSCs), 332–48
cardiac repair, 409–10
case studies, 341, 342, 343, 345
clinical experience, 342–4
definition/isolation/characterization, 333–4
functions, 340–1
future aspects, 344–5
in vitro growth, 334–5
molecular mechanisms, 335
MSC-mediated immunosuppression, 336–9
neurosurgical use, 182
off-the-shelf use, 345, 346
orthopedics, 153, 163–4
tissue engineering, 346
unqualified suppliers, 40
meshed skin grafts, 241–2
metabolism, 88, 94–5, 96, 172
methicillin-resistant Staphylococcus aureus, 118, 120
Miami, 154, 167
micro skin grafts, 245
microencapsulation, islet cells, 394–5
microkeratome-assisted ALK, 282
minor burns, treatment, 238
mobilization of stem cells, 411–12
molecular immunosuppressive mechanisms, 335–9
monetary value, human body, 9
monoclonal antibodies, 333
morbidity, bone donor sites, 171, 174
morphogens
see also cytokines; growth factors
dentistry, 228–9
mortality risk, 18–19, 125
mosquito vector, 55, 56
motor behaviors, 360, 362
mouse model, 361, 397, 411
mouth, buccal mucosa, 273, 274, 294
MRI (magnetic resonance imaging), 372, 412, 413, 416
MSCs see mesenchymal stem cells (MSCs)
mucogingival defects, 221–2, 230
multidisciplinary teams, 303–4
multiple autoimmune disease, 392
multiple ligament reconstruction, 200–1
multipotent adult progenitor cells (MAPCs), 334, 409–10
multipotent mesenchymal stem cells, 333
murine model, 290, 361, 395, 411
Murray, G., 135
*Mycobacterium*, 77, 85
*Mycoplasma hominis*, 85, 97
myeloablative conditioning, 318–19, 320, 324, 327
myocardial infarction (MI)
mesenchymal stem cells, 340, 342
rat model, 415
stem cells for cardiac repair, 403
STEMI, 405, 408, 409, 411
myoelectric prostheses, 304
β-myosin heavy chain mutation, 98, 100, 440
NAIS (neo-aorto iliac system), 125
*Nanog* transcription factor, 411
National Health Service Blood and Transplant Tissue Services (NHSBT), 26
National Medical Error Disclosure Act of 2005 (USA), 33
natural killer (NK) cells, 336
Navy Tissue Bank (US, Bethesda), xv, 154, 166, 167
*Neisseria gonorrhoeae*, 436
neo-aorto iliac system (NAIS), 125
NeoForm™, 265
neonatal alloimmune thrombocytopenia, 99–101
neural stem cell transplantation, 358–74
cell integration, 371
clinical trials, 362–6
functional cell transplantation, 360–2
future aspects for control, 370–3
 genetic stability, 371
history, 358–67
neural stem cell transplantation (cont’d)
imaging studies, 372
in vivo stability, 371
Parkinson’s disease, 363, 364–6, 367
personalized medicine, 372–3
safety, 371–2
neurodegenerative disease see neural stem cell transplantation
neurosurgery
ACDF, 171–2, 173, 174, 176, 177
bone
allografts, 170–88
autografts, 171, 173–5
bone morphogenetic proteins, 179–82
demineralized bone matrices, 178–9
spinal fusion, 171–2, 173, 174, 176, 177
substitutes, 178–9
current practice, 173–82
dural grafts, 170, 183–5
neutrophil recovery, 328
new variant CJD, 83
New York Codes, Rules and Regulations (NYCRR), 59
Ngn3 expression, 397
NHSBT (National Health Service Blood and Transplant Tissue Services), 26
nitric oxide (NO), 338
NK (natural killer) cells, 336
normative ethical framework, 4–5
Notify Project, 66
novel treatment clinical governance, 40
numbers of allografts transplanted, 73
NYCRR (New York Codes, Rules and Regulations), 59
OC (organ culture), 285
OCT4 transcription factor, 335, 411
ocular surface diseases
amniotic membrane use, 279, 286–7
CLAU procedure, 279, 280, 285
corneal transplantation, 284–6, 290
hereditary disorders, 296
KLAL procedure, 279, 289, 297
LR-CLAL procedure, 279, 285, 286, 289
off-the-shelf MSCs use, 345, 346
OHSS (ovarian hyperstimulation syndrome), 427
Olson, L., 359
oncology see cancer
oocytes
ABO compatibility, 440
donation, 433–40
donor assessment, 436–7
freezing, 428
hemolytic disease of the newborn, 99
recipient assessment/preparation/risks, 437, 438–9
retrieval, 425
ophthalmic surgery
anterior/posterior lamellar keratoplasty, 280–8, 293
case studies, 297–9
cells-based, 279, 280, 285, 289–93, 294–5, 300
penetrating keratoplasty, 278–86, 293, 300
present practice, 280–93
oral mucosa, 273, 274, 294
Orcel®, 272
organ allografts
see also vascularized composite allotransplantation (VCA)
cancer transmission, 84, 87–9
graft-versus-host disease, 90–4
infectious disease transmission, 75–87
interposition vascular conduits, 121
metabolic/genetic disease transmission, 88, 94–5, 96
organ culture (OC), 285
Organ Procurement and Transplantation Network, 306
orthopedics, 152–68
allografts current use, 154–7
articular cartilage, 153, 156–7
bone
alternatives, 164–6
current use, 154–5
demineralized matrix, 164
morphogenetic proteins, 164–5
structural allografts, 157–63
future directions, 167
mesenchymal stem cells, 163–4
Outerbridge II/III lesions, 157
soft tissues, 153, 156
Index

osteoaarthritis, 156–7, 197
osteobiologics, 164
osteochondral allografts, 198–201, 203, 204
osteochondral allografts, 198–201, 203, 204
osteogenesis, 172, 173
osteogenesis, 172, 173
osteointment, 172, 173, 179–80
osteolytic lesions case study, 158–9, 185–7
osteosarcoma, 160–3
outcomes see clinical outcomes
Outerbridge II/III lesions, 157
ova see oocytes
ovarian hyperstimulation, 424–5
syndrome (OHSS), 427
ovarian reserve assessment, 436
oversight committees, 35, 36
pain, 174, 241, 248
pancreatic islet cells, 383–400
adverse events, 389, 390
case studies, 385–6, 392, 394
clinical trials, 387–9, 398–9
donor factors, 390–1
Edmonton protocol, 386–7, 388
existing β cells proliferation, 396
history, 383–7
immunosuppression, 384, 385, 389, 393–5
manufacturing, 391
microencapsulation, 394–5
other mature cell types
reprogramming, 397–8
preclinical research, 395
present situation, 387–98
stem cells, 397
supply/demand, 390–1
transplant procedure, 389, 390
parasitic infections, 64–5, 86
Parkinson’s disease, 363, 364–6, 367
parosteal osteosarcoma, 162–3
partial thickness burns, 237–8, 262, 263
particulate bone dental allografts, 219, 220, 224, 225
passenger lymphocyte syndrome (PLS), 91, 92
patents, 373
patient information, 33, 35, 101
patient selection/suitability
composite grafts, 14, 303, 306–7
dental bone allografts, 222–3
Parkinson’s disease, neural cell transplants, 365
pre-IVF donation cycle, 436–7
recordkeeping importance, 41
payment for donation, 5, 6, 15–16
peanut allergy transmission, 94
pectoralis major tendon repair, 202
pediatrics see children
PEEK (polyetheretherketone) cages, 179
penetrating keratoplasty (PK), 278–86, 293, 300
pericranium, 184
periodontal disease, 214–17
peripheral blood stem cells, autologous, 322, 323, 329–30
peripheral vascular grafts, 124–5
personalized medicine, 372–3
PET (positron emission tomography), 119, 372, 412
PGD (pre-implantation genetic diagnosis), 428–31, 432–3
PGH (pre-implantation genetic haplotyping), 430
physicians/surgeons
biovigilance role, 63–5, 69, 79
networks, 30, 32, 101
reporting adverse events, 72, 101
clinical governance role, 23–45
details, 24–8
communication between, 97
needle-stick injury, malignancy transfer from patient, 87
PK (penetrating keratoplasty), 278–86, 293, 300
platelet-rich plasma (PRP), 227, 228
plating, neurosurgical, 176, 177, 179
PLK (posterior lamellar keratoplasty), 281, 282–3, 293
PLS (passenger lymphocyte syndrome), 91, 92
pluripotency, 368, 398–9
polyetheretherketone (PEEK) cages, 179
polyglactin mesh, 264
polymerase chain reaction (PCR), 429
porcine heart valves, 138, 139, 143
porcine type I collagen peptides, 261
porcine xenotransplants, 395
positron emission tomography (PET), 119, 372, 412
post-operative complications see biovigilance; complications; disease transmission; infections, post-op
post-transplant lymphoproliferative disease (PTLD), 90
posterior lamellar keratoplasty (PLK), 281, 282–3, 293
posterior–lateral lumbar fusion, 176
pre-implantation allograft testing, 80–1
pre-implantation genetic diagnosis (PGD), 428–31, 432–3
pre-implantation genetic haplotyping (PGH), 430
preclinical research, 395, 412–14
preconditioning, 16, 318–19, 320, 324, 327
preservation methods, 117, 136, 154, 175–6
see also cryopreservation
prioritization, body parts recovery, 10
private cord blood banking ethics, 18
processing of tissue see also cryopreservation
progenitor cells see stem cells
Project Notify, 66
PROMETHEUS clinical trial, 407
prostaglandin E2 (PGE2), 338
prostheses, 147, 304–5
proteoglycans, 263, 264
PRP (platelet-rich plasma), 227, 228
Pseudomonas aeruginosa, 81
psychosocial assessment, 303
PTLD (post-transplant lymphoproliferative disease), 90
Pybus, Charles, 383
qualification, tissue suppliers, 39
quality, 5, 6, 59, 368
rabies virus, 77, 81
radiation, 176, 332
radiotherapy, 313
rat model, 360, 364, 369
re-replacement, heart valves, 147–8
recall of tissue, 43
ReCell® kit, 271
recipient selection see patient selection
recognising adverse outcomes, 32–5, 83–5, 86
recombinant bone morphogenetic protein (rhBMP), 227
recombinant DNA technology, 180–1, 182
recombinant platelet derived growth factor (rhPDGF), 227, 228
recombinant protein therapy, 228–9
record-keeping, 29, 39, 41, 54
recurrent shoulder instability, 201
reduced-intensity conditioning regimens, 318–19, 324
REGENERATE-IHD clinical trial, 407
registries
aortic allografts, 125
biovigilance, 50, 51, 52
composite grafts, 308, 309
corneal allografts, 50
EUROCET, 20
hematopoietic stem cells, 314
pancreatic islet cells, 384, 387, 389
Serious Events and Adverse Effects, 51
Serious Product Events and Adverse Effects, 52
regulatory aspects see also biovigilance
AATB biovigilance proposal, 63–6
assisted reproduction, 432–3
international regulation, 5, 18
MSCs licensing, 338–9
neural stem cell transplantation, 373
reporting requirements, 59–61
tissue distributors, 58–9
regulatory T cells, 339
rejection of grafts see graft failure, rejection
related bone marrow donors, 15–16
remodeling see ventricular remodeling
renal cell carcinoma, 88
renal dialysis, 122
REPAIR-ACS clinical trial, 406
reporting adverse events
see also biovigilance; communication gaps
authorities, 59–61
handling/processing, 56–9
physician’s role, 72
reprogramming mature cell types, 397–8
research
see also clinical trials
pre-clinical, 395, 412–14
surgeon’s responsibilities, 27–8
resident cardiac stem cells, 410
resorbable collagen membranes, 221, 224
resource-poor countries, 17
retrieval of tissue, 9–11, 15, 16–17
retroviruses, 396
see also HIV/AIDS transmission
revascularization, 243, 244
revision joint replacements, 155
rhBMP (recombinant bone morphogenetic protein), 181, 227
Rheinwald and Green method, 269
rhPDGF (recombinant platelet derived growth factor), 227, 228
ridge resorption, dental, 224
rifampicin, 120, 125
right ventricular outflow tract (RVOT) repair, 137, 138, 141, 142
risk management see biovigilance
RNA interference technology, 396
Ross autotransplant operations, 135, 141–2
runaway dyskinesia, 365
RVOT (right ventricular outflow tract) repair, 137, 138, 141, 142
SAEs (Serious Adverse Events), 61
safety
see also biovigilance
access trade-off, 13
allograft viability relationship, 73–5
biovigilance networks, 23–45
clinical governance in relation to, 23–45
ethical issues, 6
neural stem cells, 371–2
normative ethical framework, 5, 6
physician/surgeon knowledge, 27–8
sports medicine allografts, 194–6, 208
sandwich autograft/allograft skin grafting, 245, 246, 254–5
saphenous vein grafts, 126
SAREs (Serious Adverse Reactions and Events), 61, 62
SARs (Serious Adverse Reactions), 60, 61
savior sibling HLA tissue typing, 430–1
SCA-1 cell surface marker, 410
scaffolds, 207–8, 228, 229, 290
SCIPIO clinical trial, 410
SEAR (Serious Events and Adverse Effects Registry), 51
selected hematopoietic stem cell preparations, 408–10
semen, donated, 433, 434, 435–6, 440
Sentinel Network, Transplantation Transmission (TTSN), 62–3
serial burns-wound excision/grafting, 239, 249, 251
Serious Adverse Events (SAEs), 53, 55, 61
Serious Adverse Reactions and Events (SAREs), 61, 62
Serious Adverse Reactions (SARs), 60, 61
Serious Events and Adverse Effects Registry (SEAR), 51
Serious Product Events and Adverse Effects Registry (SPEAR), 52
serum-based eye drops, 288–9, 298, 300
sexually-transmitted diseases (STDs), 97, 435–6
see also HIV/AIDS transmission
shoulder instability, 201
sibling hematopoietic stem cells, 314–15
sickle cell disease, 430, 431, 435
silicone rubber, 261, 263, 267, 268
silver-ion coated grafts, 125
site preservation, dental, 225
sizing of sports allografts, 202–3
skeletal defects, 157–63
skeletal myoblasts, 404
skeletal stem cells see bone-marrow-derived mesenchymal stem cells
skin grafting
burns, 236–56
autografts, 240–2
graft rejection, 248
history, 237
human deceased donor, 237, 240, 242–9, 251–4
meshed, 241–2
resource planning, 251–2
sandwich autograft/allograft, 245, 246, 254–5
substitutes, 249–51, 254, 255
keratinocytes, 269–71
non-burn applications, 272–4
skin substitutes, 258–76
composite grafts, 271–4
cultured epithelial, 269–71
dermal, 260–1, 263–9
epidermal, 260–3
ideal, 240, 241
temporary dressings, 259–60
urethroplasty, 273
smoking, 172, 177, 179, 223
soft tissues see also connective tissue
dentistry, 226–7
orthopedics, 156
sports medicine, 197–8, 199
solid-organ allografts see organ allografts
SOX2 transcription factor, 335, 411
SPEAR (Serious Product Events and Adverse Effects Registry), 52
spine
anterior cervical, 171, 173, 174, 176, 177
bone allografts fusion, 154–5
cord trauma, 363, 366
split-thickness skin grafts, 265
sports medicine, 193–209
allografts
clinical outcomes, 203–5
future applications, 205–8
general risks, 194–6
history, 193–4
immunologic response, 196
indications, 197–8, 199
sizing, 202–3
tissue treatment protocols, 196–7
spray delivery, keratinocytes, 270–1
SSEA-4 transcription factor, 335
ST elevation myocardial infarction (STEMI), 405, 408, 409, 411
staged procedures, 285
standards
biovigilance systems, 56–9
EUSTITE, 53–4, 61–2, 65
heart valve decontamination, 140
neural stem cells, 368–9
Staphylococcus spp.
S. aureus, methicillin-resistant, 118, 120
S. epidermidis, 81
staphylococcal scalded skin syndrome, 246, 247
stem cells see also hematopoietic stem cell transplantation (HSCT);
mesenchymal stem cells (MSCs); neural stem cell transplantation
cardiac repair, 403–17
bone marrow mononuclear cells, 404–10
clinical issues, 412–16
future cell preparations, 410–11
resident cardiac stem cells, 410
skeletal myoblasts, 404
stem cell mobilization, 411–12
dentistry, 228, 229, 230
neurodegeneration, 358–74
ophthalmic surgery, 279, 280, 285, 289–93, 294–5, 300
pancreatic islet cells, 397
STEMI (ST elevation myocardial infarction), 405, 408, 409, 411
stenosis, adult bicuspid aortic, 146
sterilization, 50, 73, 136, 196–7
Stevens–Johnson syndrome, 246, 263, 278, 290, 295
 stewardship, 4, 5, 6, 10
 storage
 allograft heart valves, 140
 bone, 154
 clinical governance, 39, 41
 corneas, 285
 ethical aspects, 8
 records, 41, 42
 striatal lesions, 362, 363
 STRO-3 antibody, 333
 stroke, 362, 363, 366, 369
 structural bone allografts, 157–63, 176
 subsidence, bone allografts, 173, 177
 substitutes
 neurosurgery
 bone, 178–9, 181
 dura mater, 184
 orthopedics, bone, 165–6
 skin
 burns treatment, 249–51, 254, 255, 258–72, 275–6
 non-burns applications, 272–4
 supply/demand
 see also tissue suppliers
 clinical governance, 23, 24
 embryonic neural stem cells, 368
 ethical issues, 9
 pancreatic islet cells, 390–1
 Supratel®, 263
 surgeons see physicians/surgeons
 surgical trauma, 283
 surrogate mothers/carriers, 96, 99, 101
 surveillance see biovigilance
 SWISS-AMI clinical trial, 406
 synthetic bone substitutes, 165–6, 178–9, 181
 systems development
 biovigilance networks, 48–69
 AATB’s role, 63–6
 Bologna Initiative, 66
 current systems, 61–3
 history, 49–52
 need for, 52–3
 Project Notify, 66
 reporting requirements, 59–61
 risk management, 53–5
 standards/policies, 56–9
 universal coding, 66–7
 T cells, MSC-induced, 336, 337, 338–9
 T regulatory cells (T_{reg}), 339
 TAC-HFT clinical trial, 407
 taco configuration, 283
 take (skin grafts), 243–4, 269
 Tay–Sachs disease, 435
 TBSA (total burn surface area), 251, 252
 tear supplements, 288–9, 298
 TEBM (tissue-engineered buccal mucosa), 274
 teeth see dentistry
 temporalis fascia, 184
 temporary biosynthetic wound dressings, 261–3
 tendon allografts, 201
 terminology, 7–8, 51, 237–8, 305–6, 307
 terrorism, 252–3
 testicular tissue freezing, 428
 tetralogy of Fallot, 141, 145–6
 TGF-α (transforming growth factor α), 263
 TGF-β (transforming growth factor β), 287, 337, 339
 (β)-thalassemia, 430
 thoracic osteolytic lesions, 185–7
 thrombocytopenia, 94, 99–101
 thymidine labeling, 359
 thymus, 328
 tibial osteosarcoma, 160–2
 tibiofemoral joint see knee surgery
 TIME clinical trial, 406
 timing of ocular procedures, 285
 tissue banks
 AATB biovigilance standards, 58–9
 bone, 152, 154, 155
 organization, 166
 disease transmission, 78, 79
 HIV/AIDS testing, 195
tissue banks (cont’d)
qualifications/certification, 39
skin, 247–8
tissue engineering
conjunctiva, 295
dentistry, 228–31
mesenchymal stem cells, 340–1, 346
ocular endothelium, 295–6
vascular allografts, 128–9
tissue matching, 138
see also ABO compatibility; human
leukocyte antigen (HLA)
compatibility
tissue-engineered buccal mucosa
(TEBM), 274
TNF-α (tumor necrosis factor-α), 338
Toll-like receptors (TLRs), 339
tooth extraction/loss, 217
total body irradiation, 313
preconditioning, 16, 318–19, 320,
324, 327
total burn surface area (TBSA), 251, 252
toxic epidermal necrolysis, 246, 247,
263
traceability
biovigilance, 29, 30
failures, 57, 58
clinical governance, 39, 43
inadequate/false, 54
universal coding, 66–7
tracheal reconstruction, 122
training, surgeons/physicians, 26
Transcyte® (Dermagraft-TC®), 262–3
transdifferentiation of MSCs, 341, 342
transfer RNA (tRNA), 337
transformation, malignant, 344, 348
transforming growth factor α (TGF-α),
263
transforming growth factor β (TGF-β),
287, 337, 339
transmissible spongiform
eencephalopathies (TSEs), 65,
82–3, 85, 183, 184
see also Creutzfeldt–Jakob Disease
(CJD)
transmission of disease see disease
transmission
transparency
ethics, 4, 5, 6
patient information, 33, 35, 101
Transplantation Transmission Sentinel
Network (TTSN), 62–3
transport of allograft heart valves, 136
tricalcium phosphate, 179
Trichomonas vaginalis, 97
tritiated thymidine labeling, 359
TSEs see transmissible spongiform
eencephalopathies (TSEs)
TTSN (Transplantation Transmission
Sentinel Network), 62–3
tubal damage, 422
tuberculosis, 77, 85
tumor necrosis factor-α (TNF-α), 338
tumors see cancer
Tutoplast® dura mater allografts, 83
UCBT (unrelated umbilical-cord blood
transplantation), 317–18, 327
umbilical cord blood (UCB), 18,
317–18, 327, 369–70
United kingdom
consensus donor selection algorithm,
325
Human Fertilisation and Embryology
Authority, 432, 433
National Health Service Blood and
Transplant Tissue Services, 26
receipt/storage of tissues, 37, 38
United States
biovigilance system development,
AATB’s role, 63–6
biovigilance systems development,
52–3, 57, 58
blood banking, error reporting, 55
Centers for Disease Control and
Prevention, 55, 195, 196
muskuloskeletal allografts safety,
195, 196
risk management, 55
College of American Pathologies,
56–7
Cornea Donor Study Investigator
Group, 278–9
Food & Drug Administration, 370
human embryonic stem cell
transplantation, 370
National Healthcare Safety Network,
63
National Medical Error Disclosure Act
of 2005, 33
Navy Tissue Bank (Bethesda), xv, 154, 166, 167
New York Codes, Rules and Regulations, 59
receipt/storage of tissues, 37, 38
Transplantation Transmission Sentinel Network, 62–3
University of Miami Tissue Bank, 154, 167
unprocessed tissues safety risk, 73
unrelated adult volunteer HSC donors, 315–16, 322, 323
unrelated umbilical-cord blood transplantation (UCBT), 317–18, 327
unselected cell preparations, 404–8
Ureaplasma urealyticum, 97
urethroplasty, 273
Urist, Marshall, 179
uterine cavity, 437
vascular allografts, 114–31
graft infection, 119–21
late aneurysmal degeneration, 117–18, 127, 128, 131
clinical trials, 123
costs, 129–30
cryopreservation, 127–8
current position, 125–6
dialysis access, 122
donor-pool insufficiency, 129
early preservation methods, 117
evidence available, 122–3
future use, 128–30
global aspects, 128
history, 114, 115, 116–18
immunology, 126–7
indications for use, 118–19
pediatric congenital cardiac disease, 122
peripheral graft infection, 124–5
post-op graft infections, 119–21
saphenous vein grafts, 126
tissue engineering, 128–9
traceal reconstruction, 122
tumor resection/reconstruction, 121
xenografts, 127
vascular conduits see cardiovascular disease, cardiac valves/conduits
vascular endothelial growth factor (VEGF), 411
vascular-rich cavities, 360
vascularization, 243, 244, 273–4
vascularized composite allotransplantation (VCA), 302–9
clinical outcomes, 308–9
donor selection/suitability, 306
emotional aspects, 307–8
face transplants, 303, 305, 306, 307–9
future aspects, 309
hand transplants, 303, 304–5, 307–8, 309
history, 302–3
immunosuppression, 307
multidisciplinary teams, 303–4
present situation, 305–9
recipient selection, 306–7
veno-occlusive disease, 320, 321
ventricular remodeling, adverse, 403, 408
viability of allografts
allograft heart valves, 140
chondrocytes, 194, 198–9, 200
osteochondral allografts, 194, 198–9, 200
safety relationship, 73–5
skin, 243
viral infections, 81–2
see also hepatitis C virus (HCV); HIV/AIDS transmission
AATB-accredited tissue banks, 195
biovigilance networks, 64–5
cytomegalovirus, 77, 81, 248, 394
Epstein–Barr virus, 77, 90
hepatitis B virus, 75, 76, 77, 81, 97
herpes simplex virus, 81
human T-cell lymphotropic virus, 75, 76, 77, 81
lymphocytic choriomeningitis virus, 86
porcine xenotransplants, 395, 396
rabies virus, 77, 81
sports medicine, 194–5
West Nile virus, 55
vitrification, 143
water drains as infection source, 44
West Nile virus, 55
WHO Guiding Principles on fees, 10, 11
Wolff’s law, 173
World Health Organization (WHO), 59
World Marrow Donor Association, 51
wounds
see also skin grafting
burns
characteristics, 258
closure, 239–40, 244
contraction, 264
dressings, temporary biosynthetic, 261–3
excision, 239, 249, 251
healing, 237–8
X-linked recessive diseases, 430, 435
xenografts
dural, 184–5
pancreatic islet cells, 395–6, 399
porcine heart valves, 138, 139, 143
vascular, 127
cardiac, 138, 139, 141
Zirm, Edward K., 278